Breaking News
Investing Pro 0
🚨 Our Pro Data Reveals the True Winner of Earnings Season Access Data

'The right path' - Chile defends Sinovac use amid fresh efficacy questions

Stock Markets Apr 11, 2021 06:10PM ET
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. FILE PHOTO: A woman holds a small bottle labeled with a "Coronavirus COVID-19 Vaccine" sticker and a medical syringe in front of displayed China flag in this illustration
 
PFE
+1.40%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
JNJ
+0.88%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
AZN
-0.71%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 
MRNA
-2.66%
Add to/Remove from Watchlist
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

By Aislinn Laing

SANTIAGO (Reuters) - Chilean authorities on Sunday backed the country's widespread use of the COVID-19 vaccine manufactured by Chinese firm Sinovac after China's top disease official appeared to make conflicting statements about its efficacy.

Gao Fu, the director of the Chinese Centers for Disease Control and Prevention, told a conference in the Chinese city of Chengdu on Saturday that the country was considering mixing COVID-19 vaccines since currently available vaccines "don't have very high rates of protection."

He later said in an interview with state media that his comments were "completely misunderstood."

Available data shows Chinese vaccines lag behind others including Pfizer (NYSE:PFE) and Moderna (NASDAQ:MRNA) in terms of efficacy, but require less stringent temperature controls during storage.

The COVID-19 vaccine developed by China's Sinovac was found to be just over 50% effective in reducing infection in Brazilian clinical trials. A real-world study of vaccination and contagion data by the University of Chile suggested last week the vaccine was 54% effective in reducing infection.

Chile paid $3.5 million to host a clinical trial of the vaccine and has also ordered 60 million doses to be administered to its 18 million-strong population over three years.

The country has largely relied on the Sinovac vaccine, along with smaller numbers of Pfizer's equivalent drug, to roll out one of the world's fastest vaccination campaigns, so far inoculating 4.6 million people with two doses and 7.2 million with one.

Chile also signed deals for the supply of vaccines from western drugmakers Johnson & Johnson (NYSE:JNJ) and AstraZeneca (NASDAQ:AZN) but these are yet to materialise because of supply bottlenecks.

On Sunday, Chilean science minister Andres Couve said it was important to focus on the data and the vaccine's effectiveness in reducing illness that required medical treatment or being hospitalized or dying, which it achieved in the Brazilian study in 83.7% and 100% of cases respectively.

He said Chile's health ministry will shortly publish a real world study on the effectiveness of both vaccines rolled out in its population and appealed to Chileans to continue to participate in the vaccination programme.

Heriberto Garcia, director of Chile's Public Health Institute which greenlighted CoronaVac's emergency roll-out, said people should not pay attention to headlines.

"The University of Chile study and the study the health ministry will release say the same thing: the number of people who fall ill and are hospitalized has decreased," he told local newspaper La Tercera. "We are going down the right path."

'The right path' - Chile defends Sinovac use amid fresh efficacy questions
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with other users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind:  

  •            Enrich the conversation, don’t trash it.

  •           Stay focused and on track. Only post material that’s relevant to the topic being discussed. 

  •           Be respectful. Even negative opinions can be framed positively and diplomatically. Avoid profanity, slander or personal attacks directed at an author or another user. Racism, sexism and other forms of discrimination will not be tolerated.

  • Use standard writing style. Include punctuation and upper and lower cases. Comments that are written in all caps and contain excessive use of symbols will be removed.
  • NOTE: Spam and/or promotional messages and comments containing links will be removed. Phone numbers, email addresses, links to personal or business websites, Skype/Telegram/WhatsApp etc. addresses (including links to groups) will also be removed; self-promotional material or business-related solicitations or PR (ie, contact me for signals/advice etc.), and/or any other comment that contains personal contact specifcs or advertising will be removed as well. In addition, any of the above-mentioned violations may result in suspension of your account.
  • Doxxing. We do not allow any sharing of private or personal contact or other information about any individual or organization. This will result in immediate suspension of the commentor and his or her account.
  • Don’t monopolize the conversation. We appreciate passion and conviction, but we also strongly believe in giving everyone a chance to air their point of view. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.
  • Any comment you publish, together with your investing.com profile, will be public on investing.com and may be indexed and available through third party search engines, such as Google.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
Comments (2)
Ad Cline
Ad Cline Apr 11, 2021 8:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
looks like fell for the Chinese doctored statistics about sinovacs effectiveness. when are nations going to wake up to the costs of dealing with the treachery of China.
David David
David9 Apr 11, 2021 8:34PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
That's is not true, this is western propaganda. SinoVac is the best vaccine right now.... that is why many are waiting for it...
andrew alfred
andrew alfred Apr 11, 2021 6:14PM ET
Saved. See Saved Items.
This comment has already been saved in your Saved Items
Yea yea yea more fakes news stock market will go up up up
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email